May 1, 2024

Meritudio, a leading provider of advanced bioinformatics solutions, is proud to announce the successful development of a comprehensive research database for KYinno, a preclinical contract research organization (CRO) with decades of experience. The database, accessible at https://innopedia.kyinno.com, features two key modules: the Tumor Models Module and the Antibody Module, providing researchers with a powerful, all-in-one resource for oncology research.

A Customized Database for KYinno

Meritudio collaborated closely with KYinno to design and deliver this tailored database, leveraging its expertise in bioinformatics and its renowned Tumor Models Database as the foundation for the Tumor Models Module.

The Tumor Models Module hosts comprehensive genomics and pharmacology information for over 650 cancer cell lines and nearly 700 engineered cell lines, making it an invaluable resource for researchers studying tumor biology and developing new therapies.

In addition, Meritudio developed the Antibody Module, which offers detailed insights into antibody data, including target specificity, binding affinity, and applications in cancer research. Together, these modules create a unique and versatile tool for researchers.

Freely Accessible to the Global Research Community

Reflecting the shared commitment of Meritudio and KYinno to advancing cancer research, the database is freely accessible to all users without the need for registration. Researchers, scientists, and clinicians are invited to explore the database’s two modules. Whether you’re studying tumor biology, developing new therapies, or searching for antibody-related insights, the database is designed to meet your research needs.

About KYinno

KYinno is a preclinical contract research organization (CRO) with decades of experience, providing customized services in in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and groundbreaking antibody discovery. Powered by its unique proprietary assets, including 3000+ engineered cell lines, bispecific and tri-specific antibody discovery mouse models, the 5000-antibody specificity screening MPSA-AB5000 panel, and the KY-AITM antibody development artificial intelligence platform, KYinno is at the forefront of innovative preclinical research. Learn more at http://www.kyinno.com.

About Meritudio

Meritudio is a leader in bioinformatics solutions, specializing in cloud-based platforms and tailored services designed to supercharge research and development in life sciences. With a powerhouse team of biologists, bioinformaticians, data scientists, and statisticians, we strive to achieve scientific excellence and facilitate groundbreaking discoveries. Connect with us at http://www.meritudio.com or contact us at bd@meritudio.com

December 22, 2023

Meritudio is proud to announce its pivotal role in the development of ChemPartner's newly launched Biology Database (https://database.chempartner.com), a platform set to revolutionize access to diverse tumor models and accelerate pharmaceutical breakthroughs.

Developed by Meritudio, this innovative database serves as a centralized hub for ChemPartner's clientele, providing seamless access to an extensive collection of preclinical research data. The database encompasses over 1000 tumor models spanning more than 30 cancer types, insights into 20,000 genes, details on 2,300 pathways, and over 1,800 standards of care (SoC) data points from literature and internal sources, complemented by 30+ analytic modules.

The sophisticated infrastructure provided by Meritudio enables the Biology Database to offer features such as:

-Unified Data Hub: Integration of dispersed tumor model data into a single, accessible resource.

-Detailed Annotations: Comprehensive genomics, pathology, and pharmacology data for each model.

-Rapid Search and Filtering: Tools for locating models based on specific criteria like cancer type and genomic features.

-Data Analysis and Mining: Support for drug mechanism analysis and biomarker discovery.

-Data Visualization: Clear presentation of complex information through intuitive charts and statistics.

"The successful launch of this database underscores our commitment to delivering cutting-edge solutions that empower researchers," stated by Meritudio. "We are thrilled to have collaborated with ChemPartner to provide the scientific community with a powerful tool that can significantly enhance the efficiency and effectiveness of drug development efforts."

About Meritudio

Meritudio is a leader in bioinformatics solutions, specializing in cloud-based platforms and tailored services designed to supercharge research and development in life sciences. With a powerhouse team of biologists, bioinformaticians, data scientists, and statisticians, we strive to achieve scientific excellence and facilitate groundbreaking discoveries. Connect with us at http://www.meritudio.com or contact us at bd@meritudio.com